Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 8,507,505

Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,507,505

Title:	Dihydropyrazolopyrimidinone derivative
Abstract:	The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar.sup.1 is an optionally substituted aryl or heteroaryl group; R.sup.1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; R.sup.2 is an optionally substituted aryl, aralkyl, or heteroaryl group; and R.sup.3 is a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Wee1 kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy. ##STR00001##
Inventor(s):	Bamba; Makoto (Ibaraki, JP), Furuyama; Hidetomo (Kanagawa, JP), Sakamoto; Toshihiro (Ibaraki, JP), Sunami; Satoshi (Ibaraki, JP), Takahashi; Keiji (Chiba, JP), Yamamoto; Fuyuki (Ibaraki, JP), Yoshizumi; Takashi (Ibaraki, JP)
Assignee:	MSD K.K. (Chiyoda-Ku, Tokyo, JP)
Application Number:	13/133,673
Patent Claims:	see list of patent claims

Details for Patent 8,507,505

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Merck	ELSPAR	asparaginase	VIAL	101063	001	1978-01-10	➤ Sign Up	MSD K.K. (Chiyoda-Ku, Tokyo, JP)	2028-12-12	RX		search
Chiron	PROLEUKIN	aldesleukin	VIAL	103293	001	1992-05-05	➤ Sign Up	MSD K.K. (Chiyoda-Ku, Tokyo, JP)	2028-12-12	RX		search
Genentech	RITUXAN	rituximab	VIAL	103705	001	1997-11-26	➤ Sign Up	MSD K.K. (Chiyoda-Ku, Tokyo, JP)	2028-12-12	RX		search
Eisai Inc	ONTAK	denileukin diftitox	VIAL	103767	001	1999-02-05	➤ Sign Up	MSD K.K. (Chiyoda-Ku, Tokyo, JP)	2028-12-12	RX	Orphan	search
Genentech	HERCEPTIN	trastuzumab	VIAL; INTRAVENOUS	103792	001	1998-09-25	➤ Sign Up	MSD K.K. (Chiyoda-Ku, Tokyo, JP)	2028-12-12	RX	Orphan	search
Genzyme	CAMPATH	alemtuzumab	VIAL; INTRAVENOUS	103948	001	2001-05-07	➤ Sign Up	MSD K.K. (Chiyoda-Ku, Tokyo, JP)	2028-12-12	RX	Orphan	search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 8,507,505

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Publication Date
Australia	2009325398	Jun 17, 2010
Canada	2745970	Jun 17, 2010
European Patent Office	2376493	May 30, 2012
European Patent Office	2376493	Oct 05, 2016
European Patent Office	2376493	Oct 19, 2011
Japan	2012511502	May 24, 2012
>Country	>Patent Number	>Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.